A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma
Latest Information Update: 14 May 2024
At a glance
- Drugs Calaspargase pegol (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Nelarabine (Primary) ; Pegaspargase (Primary) ; Tioguanine (Primary) ; Vincristine (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Apr 2024 Planned initiation date changed from 18 Apr 2024 to 9 Aug 2024.
- 22 Jan 2024 New trial record